Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: MGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.33
1 Year Target Price $27.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.12% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 612.21M USD | Price to earnings Ratio - | 1Y Target Price 27.33 |
Price to earnings Ratio - | 1Y Target Price 27.33 | ||
Volume (30-day avg) 5 | Beta 1.3 | 52 Weeks Range 3.94 - 8.98 | Updated Date 09/14/2025 |
52 Weeks Range 3.94 - 8.98 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1213.57% |
Management Effectiveness
Return on Assets (TTM) -42.42% | Return on Equity (TTM) -379.54% |
Valuation
Trailing PE - | Forward PE 1.61 | Enterprise Value 660508299 | Price to Sales(TTM) 16.15 |
Enterprise Value 660508299 | Price to Sales(TTM) 16.15 | ||
Enterprise Value to Revenue 17.42 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 80447504 | Shares Floating 31695501 |
Shares Outstanding 80447504 | Shares Floating 31695501 | ||
Percent Insiders 24.15 | Percent Institutions 64.97 |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC is a gene therapy company founded in 2015. It focuses on developing and commercializing innovative gene therapies for patients with serious diseases. It has undergone several clinical trials and strategic partnerships to advance its pipeline.
Core Business Areas
- Gene Therapy Development: Focuses on developing gene therapies for inherited retinal diseases, salivary gland conditions, and neurological diseases.
- Manufacturing and Clinical Trials: Involves manufacturing gene therapy products and conducting clinical trials to evaluate their safety and efficacy.
Leadership and Structure
The company has a management team led by the CEO and a board of directors providing oversight. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- AAV2-hAQP1 for Radiation-Induced Xerostomia: Gene therapy product for treating radiation-induced xerostomia (dry mouth). Currently in clinical trials. Competitors include salivary gland stimulants like pilocarpine and cevimeline, as well as supportive care treatments. Revenue currently negligible as it awaits FDA approval. Market share is speculative until product launch.
- Botaretigene Sparoparvovec (AAV2-RPGR) for X-linked Retinitis Pigmentosa (XLRP): Gene therapy targeting XLRP. Partnered with Janssen Pharmaceuticals. Competitors are focused on traditional management of RP symptoms with no specific gene therapy approved for XLRP, competitors include BioMarin Pharmaceutical and ProQR Therapeutics. Revenue is contingent on successful trials and commercialization, expected in 2025.
Market Dynamics
Industry Overview
The gene therapy industry is experiencing rapid growth, driven by advancements in technology and increasing success in clinical trials. Regulatory pathways are becoming more defined, facilitating approvals and commercialization.
Positioning
MeiraGTx is positioned as a leader in gene therapy development, particularly in ocular and salivary gland indications. Its competitive advantage lies in its proprietary technology and strategic partnerships.
Total Addressable Market (TAM)
The gene therapy market is expected to reach hundreds of billions of dollars. MeiraGTx is positioned to capture a significant share of the market for its targeted indications, especially once they receive FDA approvals.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Strong intellectual property portfolio
- Strategic partnerships with leading pharmaceutical companies
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- High research and development costs
- Regulatory hurdles and approval timelines
- Manufacturing complexities
- Dependence on clinical trial outcomes
- Limited commercial experience
Opportunities
- Expanding pipeline into new therapeutic areas
- Securing regulatory approvals for lead product candidates
- Commercializing gene therapy products in key markets
- Acquiring complementary technologies or companies
- Collaboration opportunities
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Pricing and reimbursement pressures
- Patent challenges
Competitors and Market Share
Key Competitors
- SPHR
- BMRA
- CRSP
- EDIT
- NTLA
- VRTX
- BLUE
Competitive Landscape
MeiraGTx is a smaller player compared to established pharmaceutical giants. Success depends on the clinical success of its drugs and partnerships with bigger players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical trial milestones and partnerships. Growth is projected to be linear and volatile until commercialization is achieved.
Future Projections: Future projections rely on successful commercialization of gene therapy products. Analyst estimates vary, but project significant revenue growth in the mid to long term.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing regulatory designations, and expanding manufacturing capabilities.
Summary
MeiraGTx is a gene therapy company with potential, but it operates in a high-risk, high-reward industry. Strong points include their intellectual property and partnerships with Janssen. Areas to monitor are its clinical trial outcomes, regulatory approvals, and its ability to secure funding and manage resources until commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company presentations
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share data may be estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 386 | Website https://meiragtx.com |
Full time employees 386 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.